The various genetic lesions promoting aberrant activation of Akt1 in cancer patients and the availability of drugs with different mechanisms of action highlight the opportunity for a mechanism-based matching of patients and individualized treatment to effectively abrogate intrinsic tumour cell radioresistance. The gene discussed is AKT1; the disease is neoplasm.